Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

NCT06862739 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus
Type 2 DM

Interventions

COMBINATION_PRODUCT: Empagliflozin+Linagliptin+Metformin

Sponsor

Nabiqasim Industries (Pvt) Ltd